Observational studyPloS one2013
Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity.
Observational study in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 64 citations in OpenAlex.
- Impact of Naturally Composed and Size-Excluded Hymenoptera Venom Preparations on the Safety and Efficacy of Venom Immunotherapy: A Monocentric Experience.International archives of allergy and immunology · 2026Article
- Anaphylaxis after stings byHuman vaccines & immunotherapeutics · 2025Article
- Hymenoptera venom allergy in children.Italian journal of pediatrics · 2024Review
- Immunologic, genetic, and ecological interplay of factors involved in allergic diseases.Frontiers in allergy · 2023Review
- Article
- Component-Resolved Evaluation of the Risk and Success of Immunotherapy in Bee Venom Allergic Patients.Journal of clinical medicine · 2022Article
- Observational
- Benefits and limitations of sting challenge in hymenoptera venom allergy.Allergologie select · 2021Article
- Expression of eosinophils, RANTES and IL-25 in the first phase of Hymenoptera venom immunotherapy.Postepy dermatologii i alergologii · 2020Article
- The Honeybee Venom Major Allergen Api m 10 (Icarapin) and Its Role in Diagnostics and Treatment of Hymenoptera Venom Allergy.Current allergy and asthma reports · 2020Review
- IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper.The World Allergy Organization journal · 2020Article
- Hymenoptera Venom Allergy: How Does Venom Immunotherapy Prevent Anaphylaxis From Bee and Wasp Stings?Frontiers in immunology · 2019Review
- Component-resolved evaluation of the content of major allergens in therapeutic extracts for specific immunotherapy of honeybee venom allergy.Human vaccines & immunotherapeutics · 2017Article
- Safety and efficacy of venom immunotherapy: a real life study.Postepy dermatologii i alergologii · 2017Article
- Which immunotherapy product is better for patients allergic to Polistes venom? A laboratory and clinical study.PloS one · 2017Article
- Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement.The World Allergy Organization journal · 2016Article
- Anaphylaxis to insect venom allergens: role of molecular diagnostics.Current allergy and asthma reports · 2015Review
- Multi-organ dysfunction secondary to severe wasp envenomation.International journal of emergency medicine · 2015Article
- Stinging insect allergy: current perspectives on venom immunotherapy.Journal of asthma and allergy · 2015Review
- [Sting challenge: indications and execution].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 12 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTreatment failure during venom immunotherapy (VIT) may be associated with a variety of risk factors.
objectiveOur aim was to evaluate the association of baseline serum tryptase concentration (BTC) and of other parameters with the frequency of VIT failure during the maintenance phase.
methodsIn this observational prospective multicenter study, we followed 357 patients with established honey bee or vespid venom allergy after the maintenance dose of VIT had been reached. In all patients, VIT effectiveness was either verified by sting challenge (n = 154) or patient self-reporting of the outcome of a field sting (n = 203). Data were collected on BTC, age, gender, preventive use of anti-allergic drugs (oral antihistamines and/or corticosteroids) right after a field sting, venom dose, antihypertensive medication, type of venom, side effects during VIT, severity of index sting reaction preceding VIT, and duration of VIT. Relative rates were calculated with generalized additive models.
results22 patients (6.2%) developed generalized symptoms during sting challenge or after a field sting. A strong association between the frequency of VIT failure and BTC could be excluded. Due to wide confidence bands, however, weaker effects (odds ratios <3) of BTC were still possible, and were also suggested by a selective analysis of patients who had a sting challenge. The most important factor associated with VIT failure was a honey bee venom allergy. Preventive use of anti-allergic drugs may be associated with a higher protection rate.
interpretationIt is unlikely that an elevated BTC has a strong negative effect on the rate of treatment failures. The magnitude of the latter, however, may depend on the method of effectiveness assessment. Failure rate is higher in patients suffering from bee venom allergy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.